35010-32-3 Usage
Uses
Used in Pharmaceutical Industry:
2-Nitro-4,5-bis(trifluoromethyl)benzenamine is used as a synthetic precursor for the development of various pharmaceuticals. Its reactivity allows for the creation of a range of medicinal compounds, contributing to the advancement of drug discovery and therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Nitro-4,5-bis(trifluoromethyl)benzenamine serves as a key intermediate in the synthesis of pesticides and other agrochemical products. Its role in these syntheses is crucial for enhancing crop protection and improving agricultural yields.
Used as a Reagent in Organic Synthesis:
Beyond its applications in pharmaceuticals and agrochemicals, 2-Nitro-4,5-bis(trifluoromethyl)benzenamine is also utilized as a reagent in organic synthesis. Its high reactivity makes it a valuable component in various chemical reactions, facilitating the production of a wide array of organic compounds for different industries.
Check Digit Verification of cas no
The CAS Registry Mumber 35010-32-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,5,0,1 and 0 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 35010-32:
(7*3)+(6*5)+(5*0)+(4*1)+(3*0)+(2*3)+(1*2)=63
63 % 10 = 3
So 35010-32-3 is a valid CAS Registry Number.
InChI:InChI=1/C8H4F6N2O2/c9-7(10,11)3-1-5(15)6(16(17)18)2-4(3)8(12,13)14/h1-2H,15H2
35010-32-3Relevant academic research and scientific papers
Glycine receptor antagonists and the use thereof
-
, (2008/06/13)
Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.
